Hanmi Pharma (128940.KS) Q1 2026: R&D at 16.6% Narrows Operating Profit 9%
*Beijing Hanmi's 22% segment margin and ₩93 billion in free cash flow cushion a quarter where accelerated R&D spending — not operational weakness — produced the year-on-year earnings shortfall.*
Source: Quarterly Report (Q1 FY2026, 17th Fiscal Year) — Filed May 15, 2026 with DART | Consolidated Financial Statements | Unit: ₩ billions
“Hanmi Pharma (128940.KS) Q1 2026: R&D at 16.6% Narrows Operating Profit 9%”
This article became available on June 19, 2026. Subscribe to read in full, or wait until September 17, 2026 when it becomes free.
Cancel anytime. Full refund within 7 days.
You just read what happened. Here's how to read what it means.
We read Hanmi Pharma's latest DART filing in full — financials under K-IFRS, governance, and what it means for the stock. PDF in your inbox in 30–40 min.
$12 · one-time
Get the Hanmi Pharma reportReading several Korean stocks a week? Get on-demand analysis on any KOSPI or KOSDAQ company, whenever you need it.
$9.99 · monthly
SubscribeIndependent journalism based on primary DART filings — not investment advice. No brokerage affiliation.
